OnCo

ABVD

Checked 2026-09-09

Classical Hodgkin lymphoma: 2-4 cycles early stage (PET-adapted), 6 cycles advanced stage

One cycle

every 28 days × 2-6 · about 8 weeks in total
1781415212228Doxorubicin: 25 mg/m², IntravenousDoxorubicinBleomycin: 10 units/m², IntravenousBleomycinVinblastine: 6 mg/m², IntravenousVinblastineDacarbazine: 375 mg/m², IntravenousDacarbazine
28-day cycle × 2-6 (about 8 weeks)Intravenous

Components

DrugDoseRouteDays
Doxorubicin
Cytotoxic chemotherapy (anthracycline)
25 mg/m²IVD1, 15
Bleomycin
Glycopeptide antibiotic (DNA-cleaving)
10 units/m²IVD1, 15
Vinblastine
Vinca alkaloid (microtubule inhibitor)
6 mg/m²IVD1, 15
Dacarbazine
375 mg/m²IVD1, 15
Cycles
2-6
28-day cycle
Emetogenicity
High (>90%)
G-CSF
Not routine

Notes

  • RATHL: drop bleomycin after a negative interim PET (AVD) with no loss of efficacy.
  • Give on schedule regardless of neutrophil count; G-CSF increases bleomycin lung toxicity.

Used in

Trials

Source

RATHL, NEJM 2016 (PET-adapted omission of bleomycin)

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers